Vaccine with dendritic cells pulsed tumoral cell line or with autologue tumor in patients with kidney carcinoma - ND
- Conditions
- kidney carcinomaMedDRA version: 6.1Level: PTClassification code 10038415
- Registration Number
- EUCTR2006-004751-38-IT
- Lead Sponsor
- OSPEDALE ONCOLOGICO DI BARI
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
1. Patients with hystologically proved MRCC
2. Good performance status
3. Life expectancy > 3 months
4. Absence of brain metastasis
5. Age < 70 years
Are the trial subjects under 18? yes
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
1. Brain metastasis
2. Active infections
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: 1. CHEMICAL: administration of the vaccine, clinical monitoring, clinical safety and efficacy, <br>2. BIOLOGICAL: methods of colture, evaluation of the biological efficacy,;Secondary Objective: 1. CHEMICAL: immunologic monitoring in vivo<br>2. BIOLOGICAL: critical and statistic evaluation of the results;Primary end point(s): Preparation of the vaccine antigenic format
- Secondary Outcome Measures
Name Time Method